Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 64

Sort by

Sort Order Select

Journal Articles

GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany

Blood (2022) 140 (4): 349–358.

https://doi.org/10.1182/blood.2021015209

Published: 2022

Includes: Supplemental data

Journal Articles

Standard of Care CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Does Bridging Efficacy Matter? a German GLA/DRST Real World Analysis

Blood (2021) 138 (Supplement 1): 3822.

https://doi.org/10.1182/blood-2021-146120

Published: 2021

Journal Articles

A Phase I Open Label Dose Escalation Study of MB-CART19.1 in Relapsed and Refractory CD19+ B Cell Malignancies, Interim Preliminary Results in Pediatric ALL, Adult ALL Including CLL Cohorts

Andreas Mackensen, Linda Hanssens, Matthias Stelljes, Wolfgang A Bethge, Tobias Feuchtinger, Annette Künkele, Michael Aigner, Alisa Yakushina, Sandra Karitzky, Silke Holtkamp, Mario Assenmacher, Marion Jurk, Georg Rauser, Dina Schneider, Claudia Rossig

Blood (2021) 138 (Supplement 1): 3836.

https://doi.org/10.1182/blood-2021-152452

Published: 2021

Journal Articles

Late Non-Relapse Mortality (NRM) after Standard-of-Care (SOC) CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Frequency, Causes, and Risk Factors.a GLA/DRST Real World Analysis

Blood (2021) 138 (Supplement 1): 1748.

https://doi.org/10.1182/blood-2021-151469

Published: 2021

Journal Articles

Two-Year Landmark Survival Analysis after Allogeneic Hematopoietic Cell Transplantation in Acute Lymphoblastic Leukemia: An Analysis from the ALWP of the EBMT

Blood (2021) 138 (Supplement 1): 1822.

https://doi.org/10.1182/blood-2021-149821

Published: 2021

Journal Articles

The CAR-Hematotox Identifies Patients at High Risk for Prolonged Neutropenia, Infectious Complications and Prolonged Hospitalization Following CD19-CART in R/R LBCL

Blood (2021) 138 (Supplement 1): 3852.

https://doi.org/10.1182/blood-2021-149579

Published: 2021

Journal Articles

Allogeneic Stem Cell Transplantation in Patients Aged ≥70 Years: Epidemiology, Outcomes, and Risk Factors Based on the German Registry for Stem Cell Transplantation (DRST)

Blood (2021) 138 (Supplement 1): 3926.

https://doi.org/10.1182/blood-2021-152349

Published: 2021

Journal Articles

External validation of models for KIR2DS1/KIR3DL1-informed selection of hematopoietic cell donors fails

Blood (2020) 135 (16): 1386–1395.

https://doi.org/10.1182/blood.2019002887

Published: 2020

Includes: Supplemental data

Journal Articles

Allogeneic Stem Cell Transplantation for MDS Patients More Than 70 Years of Age: a Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party (CMWP) of the EBMT

Blood (2015) 126 (23): 4390.

https://doi.org/10.1182/blood.V126.23.4390.4390

Published: 2015

Journal Articles

Randomized Trial on GvHD Prophylaxis with or without Anti-Human T-Lymphocyte Immunoglobulin ATG-Fresenius (ATG-F) in Allogeneic Hematopoietic Cell Transplantation from Matched Unrelated Donors: Final Long-Term Results after 8.6 Years Median Follow-up

Jürgen Finke, MD, Claudia Schmoor, PhD, Wolfgang A Bethge, MD, Hellmut Ottinger, Priv.-Doz. Dr. MD, Matthias Stelljes, Liisa Volin, MD PhD, Dominik Heim, MD, Hartmut Bertz, MD, Olga Grishina, MD, Gerard Socie

Blood (2015) 126 (23): 853.

https://doi.org/10.1182/blood.V126.23.853.853

Published: 2015

Journal Articles

Reduced Intensity Vs. Standard Conditioning Followed By Allogeneic Stem Cell Transplantation for Patients with MDS or Secondary AML: A Prospective, Randomized Phase III Study of the Chronic Malignancies Working Party of the EBMT (RICMAC-Trial)

Blood (2014) 124 (21): 320.

https://doi.org/10.1182/blood.V124.21.320.320

Published: 2014

Journal Articles

Infusion of Donor Lymphocytes Genetically Engineered to Express the Herpes Simplex Virus Thymidine Kinase (HSV-TK) Suicide Gene after Haploidentical Hematopoietic Stem Cell Transplantation (HSCT): Preliminary Efficacy Data from the Randomized TK008 Study

Blood (2014) 124 (21): 2535.

https://doi.org/10.1182/blood.V124.21.2535.2535

Published: 2014

Journal Articles

Allogeneic Stem Cell Transplantation after Conditioning with Treosulfan, Etoposide and Cyclophosphamide for Patients with Acute Lymphoblastic Leukemia (ALL) Not Eligible for TBI-Containing Regimens: A Phase II-Study on Behalf of the German ALL Study Group (GMALL) and the German Cooperative Transplant Study Group

Nicolaus Kröger, MD, Martin Bornhäuser, MD, Matthias Stelljes, Uwe Pichlmeier, Christoph Schmid, Renate Arnold, Gesine Bug, Ralf Georg Meyer, MD, Wolfgang A. Bethge, MD, Guido Kobbe, MD, Dietrich Beelen, MD

Blood (2014) 124 (21): 2461.

https://doi.org/10.1182/blood.V124.21.2461.2461

Published: 2014

Journal Articles

Self-Peptide Recognition of Posterior Eye Segment Epitopes Mediated By Allogeneic T Cells in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation

Nora Mirza, Manfred Zierhut, Andreas Korn, Antje Bornemann, Christoph Simon, Annika Boehm, Wolfgang A. Bethge, MD, Lothar Kanz, MD, Hans-Georg Rammensee, PhD, Sebastian P. Haen, MD

Blood (2014) 124 (21): 1173.

https://doi.org/10.1182/blood.V124.21.1173.1173

Published: 2014

Journal Articles

Prevention of Chronic GvHD after HLA-Identical Sibling Peripheral Hematopietic Stem Cell Transplantation with or without Anti-Lymphocyte Globulin (ATG). Results from a Prospective, Multicenter Randomized Phase III Trial (ATGfamilystudy)

Blood (2014) 124 (21): 37.

https://doi.org/10.1182/blood.V124.21.37.37

Published: 2014

Journal Articles

Allogeneic Hematopoietic Cell Transplantation For Patients With Primary and Secondary Myelofibrosis: Report Of a Single Center Experience

Christiane Dorn, MD, Sebastian P. Haen, MD, Christoph Faul, MD, Wichard Vogel, MD, Lothar Kanz, MD, Wolfgang A Bethge, MD

Blood (2013) 122 (21): 4538.

https://doi.org/10.1182/blood.V122.21.4538.4538

Published: 2013

Journal Articles

Quality Of Life After Allogeneic Stem Cell Transplantation In Patients With Myelofibrosis (CMWP of EBMT)

Nora Machate, Haefaa Alchalby, MD, Susanne Sehner, Tatjana Zabelina, MD, Daniel Wolff, MD, Guido Kobbe, MD, Martin Bornhäuser, MD, Herrad Baurmann, MD, Wolfgang A Bethge, MD, Gerald Wulf, MD, Axel R. Zander, MD, Nicolaus Kröger, MD

Blood (2013) 122 (21): 2974.

https://doi.org/10.1182/blood.V122.21.2974.2974

Published: 2013

Journal Articles

Involvement Of S100 Proteins and Hsp90 In The Pathogenesis Of Graft-Versus-Host Disease After Allogeneic Hematopoetic Cell Transplantation

Katharina Reinhardt, Dirk Föll, MD, Thomas Vogl, PhD, Falko Fend, MD, Christian Gille, MD, Tobias Feuchtinger, MD, Peter Lang, MD, Rupert Handgretinger, Wolfgang A. Bethge, MD, Ursula Holzer, MD

Blood (2013) 122 (21): 2058.

https://doi.org/10.1182/blood.V122.21.2058.2058

Published: 2013

Journal Articles

Central Nervous System Complications After Allogeneic Hematopoietic Cell Transplantation – Treatment Related Morbidity, Toxicity, Graft Versus Host Disease Or New Autoimmunity

Christoph Simon, Nora Mirza, Wolfgang A. Bethge, MD, Wichard Vogel, MD, Christoph Faul, MD, Hans-Georg Rammensee, Lothar Kanz, MD, Sebastian P. Haen, MD

Blood (2013) 122 (21): 2069.

https://doi.org/10.1182/blood.V122.21.2069.2069

Published: 2013

Journal Articles

Haploidentical Transplantation As Salvage Therapy For Disease Relapse After Allogeneic Hematopoietic Cell Transplantation

Christiane Dorn, MD, Sebastian P. Haen, MD, Christoph Faul, MD, Wichard Vogel, MD, Lothar Kanz, MD, Wolfgang A Bethge, MD

Blood (2013) 122 (21): 2084.

https://doi.org/10.1182/blood.V122.21.2084.2084

Published: 2013

NARROW

GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany

Standard of Care CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Does Bridging Efficacy Matter? a German GLA/DRST Real World Analysis

A Phase I Open Label Dose Escalation Study of MB-CART19.1 in Relapsed and Refractory CD19+ B Cell Malignancies, Interim Preliminary Results in Pediatric ALL, Adult ALL Including CLL Cohorts

Late Non-Relapse Mortality (NRM) after Standard-of-Care (SOC) CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Frequency, Causes, and Risk Factors.a GLA/DRST Real World Analysis

Two-Year Landmark Survival Analysis after Allogeneic Hematopoietic Cell Transplantation in Acute Lymphoblastic Leukemia: An Analysis from the ALWP of the EBMT

The CAR-Hematotox Identifies Patients at High Risk for Prolonged Neutropenia, Infectious Complications and Prolonged Hospitalization Following CD19-CART in R/R LBCL

Allogeneic Stem Cell Transplantation in Patients Aged ≥70 Years: Epidemiology, Outcomes, and Risk Factors Based on the German Registry for Stem Cell Transplantation (DRST)

External validation of models for KIR2DS1/KIR3DL1-informed selection of hematopoietic cell donors fails

Allogeneic Stem Cell Transplantation for MDS Patients More Than 70 Years of Age: a Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party (CMWP) of the EBMT

Randomized Trial on GvHD Prophylaxis with or without Anti-Human T-Lymphocyte Immunoglobulin ATG-Fresenius (ATG-F) in Allogeneic Hematopoietic Cell Transplantation from Matched Unrelated Donors: Final Long-Term Results after 8.6 Years Median Follow-up

Reduced Intensity Vs. Standard Conditioning Followed By Allogeneic Stem Cell Transplantation for Patients with MDS or Secondary AML: A Prospective, Randomized Phase III Study of the Chronic Malignancies Working Party of the EBMT (RICMAC-Trial)

Infusion of Donor Lymphocytes Genetically Engineered to Express the Herpes Simplex Virus Thymidine Kinase (HSV-TK) Suicide Gene after Haploidentical Hematopoietic Stem Cell Transplantation (HSCT): Preliminary Efficacy Data from the Randomized TK008 Study

Self-Peptide Recognition of Posterior Eye Segment Epitopes Mediated By Allogeneic T Cells in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation

Prevention of Chronic GvHD after HLA-Identical Sibling Peripheral Hematopietic Stem Cell Transplantation with or without Anti-Lymphocyte Globulin (ATG). Results from a Prospective, Multicenter Randomized Phase III Trial (ATGfamilystudy)

Allogeneic Hematopoietic Cell Transplantation For Patients With Primary and Secondary Myelofibrosis: Report Of a Single Center Experience

Quality Of Life After Allogeneic Stem Cell Transplantation In Patients With Myelofibrosis (CMWP of EBMT)

Involvement Of S100 Proteins and Hsp90 In The Pathogenesis Of Graft-Versus-Host Disease After Allogeneic Hematopoetic Cell Transplantation

Central Nervous System Complications After Allogeneic Hematopoietic Cell Transplantation – Treatment Related Morbidity, Toxicity, Graft Versus Host Disease Or New Autoimmunity

Haploidentical Transplantation As Salvage Therapy For Disease Relapse After Allogeneic Hematopoietic Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only